Advertisement
Advertisement
Food, herbs & supplements · health · inflammation · Emerging
Plant Compound Scutellarin Eases Pulmonary Hypertension Damage In Rats
In rats, not humansBlocks NF-κB/NLRP3 pathwayEased vessel remodelingLab cell test tooEarly-stage research
A plant-derived flavonoid called scutellarin eased pulmonary arterial hypertension in rats by shutting down an inflammatory signaling pathway, according to a study published October 8, 2026, in Pharmaceuticals.
Researchers induced pulmonary arterial hypertension, a progressive disease marked by narrowed lung arteries and right heart strain, in rats using a combination of a drug called Su5416 and low-oxygen conditions. Treating these rats with scutellarin, a flavonoid compound, improved right ventricular heart function and pulmonary blood flow measurements, while reducing pulmonary vessel remodeling and the fibrous scarring that builds up around blood vessels. Sample size was not reported in the available abstract. Separately, the authors used network pharmacology and molecular docking, computational methods that predict how a compound might bind to disease-related proteins, to identify 100 overlapping targets shared between scutellarin and pulmonary arterial hypertension, with the strongest activity centered on inflammation and pyroptosis pathways. In human pulmonary artery smooth muscle cells exposed to low oxygen in a lab dish, scutellarin reduced excessive cell growth and pyroptosis in a dose-dependent manner, meaning higher doses produced a larger effect.
The authors report that scutellarin worked by blocking the NF-κB/NLRP3 signaling pathway, a cellular alarm system that, when overactive, triggers inflammatory cytokine release and pyroptosis, a form of cell death that spills inflammatory contents into surrounding tissue. By quieting this pathway, scutellarin reduced the downstream proteins tied to pulmonary vascular remodeling, the thickening and scarring of lung arteries that drives the disease forward. Pulmonary arterial hypertension has no cure and current treatments mainly manage blood flow rather than the underlying inflammation, so a compound that targets this inflammatory root cause represents an early but meaningful lead for future drug development.
SCU ameliorates PAH-induced pulmonary vascular remodeling and right ventricular dysfunction via inhibiting the NF-κB/NLRP3 inflammatory and pyroptosis signaling cascade
Data Panel
- Who
- Su5416/hypoxia-induced rat pulmonary arterial hypertension model; sample size not reported. Human pulmonary artery smooth muscle cells used for lab-dish validation.
- Design
- In vivo rat disease model plus in vitro human cell experiments, supported by network pharmacology and molecular docking analysis.
- Dose
- Not reported in the available abstract; cell experiments used a dose-dependent range of scutellarin.
- Primary result
- Scutellarin improved right ventricular function and pulmonary hemodynamics and reduced pulmonary vascular remodeling and perivascular fibrosis in rats; exact numeric changes not reported in the abstract.
- Secondary
- Scutellarin blocked NF-κB/NLRP3 signaling, reduced inflammatory cytokine release and pyroptosis, and dose-dependently suppressed hypoxia-induced proliferation and pyroptosis in human pulmonary artery smooth muscle cells; 100 overlapping drug-disease targets identified via network pharmacology.
- Funding / conflicts
- Funding and conflicts not reported in the abstract.
This is a rat and cell-culture study; the network pharmacology and docking work is computational prediction, not direct evidence of effect in a living organism. No human data on dosing, absorption or safety exist yet, and funding and conflicts were not reported in the abstract.
Dr. Axe's Take
Scutellarin comes from Erigeron breviscapus, a plant long used in traditional Chinese medicine for circulatory support, and this rat study gives a plausible biological reason why: it calms the NF-κB/NLRP3 inflammatory switch that drives blood vessel scarring. I find this encouraging as a mechanism story, not as a treatment anyone can use today. Pulmonary arterial hypertension is a serious, specialist-managed disease, and I would never suggest a flavonoid supplement replace prescribed therapy. What I would do this week if you or a family member has any form of hypertension is focus on established anti-inflammatory nutrition, think colorful produce, fatty fish and ground flaxseed, and keep taking medications as prescribed while discussing any supplement with the treating cardiologist first.
— Dr. Axe